Role of resistant starch in improving gut health, adiposity, and insulin resistance
- PMID: 25770258
- PMCID: PMC4352178
- DOI: 10.3945/an.114.007419
Role of resistant starch in improving gut health, adiposity, and insulin resistance
Abstract
The realization that low-glycemic index diets were formulated using resistant starch led to more than a decade of research on the health effects of resistant starch. Determination of the metabolizable energy of the resistant starch product allowed for the performance of isocaloric studies. Fermentation of resistant starch in rodent studies results in what appears to be a healthier gut, demonstrated by increased amounts of short-chain fatty acids, an apparent positive change in the microbiota, and increased gene expression for gene products involved in normal healthy proliferation and apoptosis of potential cancer cells. Additionally, consumption of resistant starch was associated with reduced abdominal fat and improved insulin sensitivity. Increased serum glucagon-like peptide 1 (GLP-1) likely plays a role in promoting these health benefits. One rodent study that did not use isocaloric diets demonstrated that the use of resistant starch at 8% of the weight of the diet reduced body fat. This appears to be approximately equivalent to the human fiber requirement. In human subjects, insulin sensitivity is increased with the feeding of resistant starch. However, only 1 of several studies reports an increase in serum GLP-1 associated with resistant starch added to the diet. This means that other mechanisms, such as increased intestinal gluconeogenesis or increased adiponectin, may be involved in the promotion of improved insulin sensitivity. Future research may confirm that there will be improved health if human individuals consume the requirement for dietary fiber and a large amount of the fiber is fermentable.
Keywords: functional foods; intestinal health; nurtigenomics; obesity; resistant starch.
© 2015 American Society for Nutrition.
Conflict of interest statement
Author disclosures: C Pelkman is an employee of Ingredion, and MJ Keenan, J Zhou, M Hegsted, HA Durham, DB Coulon, and RJ Martin received funding from Ingredion.
Figures

References
-
- Pawlak DB, Bryson JM, Denyer GS, Brand-Miller JC. High glycemic index starch promotes hypersecretion of insulin and higher body fat in rats without affecting insulin sensitivity. J Nutr 2001;131:99–104. - PubMed
-
- Hausman DB, Fine JB, Tagra K, Fleming SS, Martin RJ, DiGirolamo M. Regional fat pad growth and cellularity in obese Zucker rats: modulation by caloric restriction. Obes Res 2003;11:674–82. - PubMed
-
- Sajilata MG, Singhai RS, Kulkarni PR. Resistant starch: a review. Compr Rev Food Sci Food Saf 2006;5:1–17. - PubMed
-
- Topping DL, Fukushima M, Bird AR. Resistant starch as a prebiotic and synbiotic: state of the art. Proc Nutr Soc 2003;62:171–6. - PubMed
-
- Englyst H, Wiggins HS, Cummings JH. Determination of the non-starch polysaccharides in plant foods by gas-liquid chromatography of constituent sugars as alditol acetates. Analyst 1982;107:307–18. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical